Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension

Background A majority of patients with idiopathic pulmonary arterial hypertension (IPAH) display persistent exercise intolerance despite new specific therapies. Whether patients with IPAH exhibit peripheral muscle dysfunction that may contribute to this limitation remains unknown. The hypothesis that the muscles of patients with IPAH are weaker and display morphological changes compared with those of control subjects and that those changes partly correlate with their exercise capacity was tested. Objective To characterise quadriceps function, morphology and the enzymatic profile of patients with IPAH. Methods Exercise capacity, limb muscle cross-sectional area by CT scan, quadriceps strength by maximal voluntary contraction and non-volitional magnetic stimulation of the femoral nerve (quadriceps twitch; TWq), and muscle morphology and enzymatic profile by quadriceps biopsy of 10 patients with IPAH were compared with those of 10 matched controls subjects. Results Patients with IPAH displayed a lower proportion of type I muscle fibres (p=0.05), a lower maximal voluntary contraction (p=0.05) and TWq (p=0.01), and an increased muscular phosphofructokinase/3-hydroxyacyl-CoA-dehydrogenase ratio (p=0.05). They also tended to have lower thigh muscle cross-sectional area (p=0.15). Maximal oxygen uptake correlated with quadriceps strength (R2=0.42, p=0.04), and oxygen uptake at anaerobic threshold correlated with muscle oxidative capacity assessed by oxidative enzyme level for citrate synthase (R2=0.45, p=0.05) and 3-hydroxyacyl-CoA-dehydrogenase (R2=0.86, p<0.01), and type I fibre capillarity (R2=0.57, p=0.02). Conclusion Patients with IPAH present significant peripheral muscle changes that partly correlated with their exercise capacity.

[1]  A. Torbicki,et al.  Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. , 2008, Journal of the American College of Cardiology.

[2]  K. Webb,et al.  Organization of metabolic pathways in vastus lateralis of patients with chronic obstructive pulmonary disease. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[3]  M. Humbert,et al.  Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[4]  J. Douketis,et al.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[5]  H. Katus,et al.  Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. , 2007, Respiratory medicine.

[6]  P. Wagner,et al.  Endothelin-1-mediated vasoconstriction at rest and during dynamic exercise in healthy humans. , 2007, American journal of physiology. Heart and circulatory physiology.

[7]  F. Herth,et al.  Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension , 2006, Circulation.

[8]  J. Loscalzo,et al.  Pulmonary arterial hypertension. , 2004, Annals of medicine.

[9]  D. Meads,et al.  The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension , 2006, Quality of Life Research.

[10]  H. Katus,et al.  Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension , 2005, European Respiratory Journal.

[11]  R. Naeije Breathing more with weaker respiratory muscles in pulmonary arterial hypertension , 2005, European Respiratory Journal.

[12]  R. Naeije,et al.  Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension , 2004, Circulation.

[13]  M. Polkey,et al.  Quadriceps strength assessed by magnetic stimulation of the femoral nerve in normal subjects , 2004, Clinical physiology and functional imaging.

[14]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[15]  F. Maltais,et al.  Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD , 2004, Thorax.

[16]  D. Mccrory,et al.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[17]  F. Maltais,et al.  Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[18]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[19]  R. Ross,et al.  ATS/ACCP statement on cardiopulmonary exercise testing. , 2003, American journal of respiratory and critical care medicine.

[20]  I. Piña,et al.  Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. , 2003, Circulation.

[21]  D. Chemla,et al.  Haemodynamic evaluation of pulmonary hypertension , 2002, European Respiratory Journal.

[22]  P. Kao,et al.  High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. , 2002, Chest.

[23]  M. Matsuda,et al.  Involvement of Endogenous Endothelin-1 in Exercise-Induced Redistribution of Tissue Blood Flow: An Endothelin Receptor Antagonist Reduces the Redistribution , 2002, Circulation.

[24]  M. Mador,et al.  Comparison of potentiated and unpotentiated twitches as an index of muscle fatigue , 2002, Muscle & nerve.

[25]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[26]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[27]  F. Maltais,et al.  Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. , 2001, American journal of respiratory and critical care medicine.

[28]  J. E. Hansen,et al.  Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[29]  F. Maltais,et al.  Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD , 2000, Thorax.

[30]  M. Polkey,et al.  Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man , 1995, Muscle & nerve.

[31]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[32]  J. Fridén,et al.  How to calculate human muscle fibre areas in biopsy samples--methodological considerations. , 1984, Acta physiologica Scandinavica.

[33]  K. Mabuchi,et al.  Actomyosin ATPase. II. Fiber typing by histochemical ATPase reaction , 1980, Muscle & nerve.

[34]  J. Bergström Percutaneous Needle Biopsy of Skeletal Muscle in Physiological and Clinical Research , 1975 .

[35]  P. Andersen,et al.  Capillary density in skeletal muscle of man. , 1975, Acta physiologica Scandinavica.

[36]  J. Bergstrom Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. , 1975, Scandinavian journal of clinical and laboratory investigation.